Patient case study eLearning
Find out more about the real-world use of CDK4/6 inhibitors in this expert-led EACCME®-accredited eLearning focused on case studies of women with early breast cancer (EBC)
Receive one (1) CME credit when you complete this interactive module featuring Professors Rupert Bartsch, Peter Fasching and Richard Finn.
CDK4/6 inhibitors for people with EBC
Complete these expert-presented case studies to learn about:
- The use of CDK4/6 inhibitors as adjuvant treatment for EBC in a range of real-world scenarios
- The key clinical trials underpinning their efficacy and how the latest findings may influence their use in clinical practice
- How recurrence risk impacts decisions about adjuvant therapy
Course overview
This CME module will take approximately 1 hour to complete and comprises:
- Three expert-presented patient case studies composed of two video presentations and a short, ungraded quiz
- A graded quiz consisting of 10 questions that will be available on completion of all three patient case studies. A score of 70% or higher on this quiz is required to receive 1 CME credit
- A feedback survey. Complete this survey to unlock your CME certificate
| Section | Content outline | Time (60 min total) |
| Introduction | Introduction to the module | 2 min |
| Case study 1 | Vidya, a woman with early breast cancer, 38 years of age, considering options for adjuvant therapy to reduce the risk of recurrence | 15 min |
| Case study 2 | Sara, a woman with node-positive early breast cancer and comorbidities, 58 years of age, seeking the best management options with curative intent | 15 min |
| Case study 3 | Fatima, a woman with early breast cancer, 55 years of age, pursuing further treatment after a limited response to neoadjuvant chemotherapy | 15 min |
| Knowledge assessment | Test what you have learned in this graded quiz consisting of 10 multiple choice questions | 10 min |
| Feedback survey | A short feedback survey, where you can share your experience with the eLearning module | 3 min |
Meet the experts
Professor Rupert Bartsch
Rupert Bartsch is an Associate Professor of Medicine at the Medical University of Vienna, Austria, and serves as the director of the Breast Cancer Programme at the Department of Oncology. He has a longstanding clinical and scientific focus on breast cancer and brain metastases.
Disclosures: Research funding and/or consultation fees/honoraria from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Gilead, Grünenthal, Lilly, MSD, Novartis, Pfizer, Pierre Fabre, Puma Biotechnology, Seagen, and Stemline Therapeutics.
Professor Peter Fasching
Peter Fasching, MD, is an Associate Professor of Gynecology and Obstetrics and Translational Medicine at the Friedrich-Alexander University Erlangen-Nuremberg and the National Center for Tumor Diseases WERA in Erlangen, Germany.
Professor Fasching is currently the Head of Clinical Trials Unit at the Women’s Clinic of University Hospital Erlangen, and is the Coordinator to the Breast Cancer Center and Gynecological Oncology Center as well as head of the biomaterial bank. His research focuses on cancer prevention, target discovery, big data and digital medicine.
Disclosures: Research funding and/or consultation fees/honoraria from Agendia, AstraZeneca, BioNTech, Cepheid, Daiichi Sankyo, Eisai, Gilead, Lilly, Medac, Menarini, MSD, Mylan, Novartis, Pfizer, Pierre Fabre, Roche, and Seagen.
Professor Richard Finn
Professor Richard Finn is a Professor of Clinical Medicine in the Division of Hematology/Oncology at the UCLA David Geffen School of Medicine and Director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at UCLA, California, USA.
Professor Finn currently splits his time between patient care and laboratory and clinical research. His research interests lie in the development of molecular targeted agents and biomarkers in liver cancer and breast cancer. ProfessorFinn has served as principal and sub-investigator in trials exploring the use of targeted therapies in breast and hepatocellular cancers. He has a particular interest in identifying predictive markers of response to novel therapeutics.
Disclosures: Research funding and/or consultation fees/honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, CStone Pharmaceuticals, Eisai, Genentech, Lilly, Merck, Novartis, Pfizer, and Roche.
of interest
are looking at
saved
next event